PLOS Neglected Tropical Diseases

RESEARCH ARTICLE

A miniaturized, frugal RPA assay for genus-level detection of *Paracoccidioides* spp. in resource-limited endemic settings

Melina Noelia Lorenzini Campos[1,2*], Raúl Maximiliano Acevedo[1,3], Gabriela Alejandra Massa[1,4,5], Laura Elena Valinotto[1,6], Luis Hernando Corredor Sanguña[1,2], Mario Alberto Piz[7], Raúl Horacio Lucero[2], Florencia Rojas[1,2], Laura Belén Formichelli[2], Liliana Silvina Lösch[2], Javier Esteban Mussin[1,2], Gustavo Giusiano[1,2]

1 Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Argentina, **2** Instituto de Medicina Regional (IMR), Universidad Nacional del Nordeste (UNNE), Resistencia, Argentina, **3** Instituto de Botánica del Nordeste (IBONE, CONICET), Facultad de Ciencias Agrarias, Universidad Nacional del Nordeste (UNNE), Corrientes, Argentina, **4** Instituto de Innovación para la Producción Agropecuaria y el Desarrollo Sostenible (IPADS) - Instituto Nacional de Tecnología Agropecuaria (INTA), Balcarce, Argentina, **5** Facultad de Ciencias Agrarias de la Universidad Nacional de Mar del Plata (FCA-UNMdP), Balcarce, Argentina, **6** Facultad de Medicina, Centro de investigaciones en Genodermatosis y Epidermólisis Ampollar (CEDIGEA), Universidad de Buenos Aires (UBA), Ciudad Autónoma de Buenos Aires, Argentina, **7** Facultad Regional Resistencia, Universidad Tecnológica Nacional (UTN), Resistencia, Argentina

* melinalorenzini@gmail.com

OPEN ACCESS

Citation: Lorenzini Campos MN, Acevedo RM, Massa GA, Valinotto LE, Corredor Sanguña LH, Piz MA, et al. (2026) A miniaturized, frugal RPA assay for genus-level detection of *Paracoccidioides* spp. in resource-limited endemic settings. PLoS Negl Trop Dis 20(3): e0014101. https://doi.org/10.1371/journal.pntd.0014101

Editor: Joshua Nosanchuk, Albert Einstein College of Medicine, UNITED STATES OF AMERICA

Received: December 13, 2025

Accepted: February 28, 2026

Published: March 19, 2026

Data availability statement: All sequence data generated in this study have been deposited in the GenBank database under accession

Abstract

Background

Paracoccidioidomycosis (PCM) is a neglected systemic mycosis endemic to Latin America, where diagnosis is often delayed due to limited access to rapid, simple confirmatory testing tools in resource-limited settings. This gap creates a critical need for accessible detection methods of its causative agent, *Paracoccidioides* spp., that can be deployed in frontline healthcare facilities.

Methodology/principal findings

We developed a frugal Recombinase Polymerase Amplification (RPA) assay targeting a conserved region of the internal transcribed spacer (ITS) locus for genus-level detection of *Paracoccidioides* spp. Primer specificity was evaluated *in silico* and experimentally against phylogenetically related fungi and clinically relevant pathogens, with no cross-reactivity observed. The assay robustly amplified across multiple *Paracoccidioides* lineages, and all products were validated by Sanger sequencing. The analytical limit of detection (LoD) was 1 pg of genomic DNA per 8 μL reaction, demonstrated by UV-based SYBR Green I visualization, agarose gel electrophoresis, and Qubit fluorometric assessment. Key optimizations included reaction miniaturization from 50 μL to 8 μL and a simple freeze–boil lysis compatible with crude fungal

numbers PX684487 to PX684497. https://www.ncbi.nlm.nih.gov/nuccore/PX684487, https://www.ncbi.nlm.nih.gov/nuccore/PX684497.

Funding: The author(s) received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

biomass extracts, avoiding the need for commercial extraction kits, lengthy protocols and expensive equipment.

Conclusions/significance

This RPA assay offers a rapid, affordable, and operationally simple molecular tool specifically designed for the detection of *Paracoccidioides* DNA. Its ability to work with crude lysates and miniaturized reaction volumes supports its implementation in resource-limited endemic areas. Although clinical validation remains necessary, this assay constitutes a practical foundation for expanding molecular diagnostic capacity for PCM in underserved regions. This work demonstrates how frugal methodological strategies can support equitable access to molecular detection tools.

Author summary

Paracoccidioidomycosis (PCM) primarily affects rural populations in Latin America. Rapid, accessible tools for detecting its causative agent, *Paracoccidioides* spp., are urgently needed in endemic regions. We developed a simple and low-cost molecular test based on Recombinase Polymerase Amplification (RPA) that detects *Paracoccidioides* DNA. Validated with DNA from fungal cultures after a freeze-boil cycle, this approach overcomes the need for commercial extraction kits, lengthy protocols, or specialized equipment. The assay operates at a constant low temperature, yields results within minutes, and requires only a basic UV lamp for visualization, making it suitable for small frontline healthcare facilities with limited budgets. It demonstrates high specificity, no cross-reactivity with related pathogens and reliable performance using miniaturized reaction volumes that significantly reduce per-test costs. Although evaluation with clinical samples remains a future step, this frugal and equipment-minimal assay represents a practical advance toward equitable molecular detection of this pathogen in resource-limited settings. We believe this work could meaningfully contribute to improving the diagnosis of this long-neglected disease.

1. Introduction

Paracoccidioides, a thermodimorphic fungus comprising the *P. brasiliensis* complex (S1, PS2, PS3, PS4) and *P. lutzii*, is the causative agent of paracoccidioidomycosis (PCM), considered a neglected systemic mycosis endemic to Latin America [1,2]. In 2022, the World Health Organization (WHO) included *Paracoccidioides* genus in its priority pathogens list [3]. In Argentina, the S1 lineage is prevalent and a PS3 case was detected [4]. PCM imposes a substantial clinical burden, primarily affecting rural populations with limited access to specialized healthcare. Infection typically begins with the inhalation of fungal propagules, leading to pulmonary conversion to the yeast phase and potential dissemination. Diagnostic delays, often due to limited access to

health services or diagnostic tools in some regions, but also to low clinical suspicion given the nonspecific clinical manifestations, become especially critical in acute/subacute presentations, which progress rapidly in children and young adults [5–8]. Biological factors further compound these challenges, including the fungus's robust cell wall [9,10], low fungal burden in some clinical specimens, and the slow, technically demanding growth of cultures [11].

Current PCM diagnosis relies on a combination of conventional methods, each of which has significant limitations. Direct microscopic examinations are quick and inexpensive but require an experienced operator. The sensitivity of this method depends on the type of clinical sample, sometimes the fungal load is low and obtaining such a sample is not always feasible. Fungal recovery in culture is also a reference for definitive diagnosis. However, this process can take several weeks, has low sensitivity, and is often unavailable in low-complexity laboratories. Histopathology provides valuable information on tissue involvement but requires invasive sampling and specialized expertise. Likewise, turnaround times are generally not short. There are no commercial tests for antibody detection. In house serological assays are used in most referral centers in endemic areas and are also useful for monitoring. However, cross-reactivity, variable sensitivity among clinical forms, and reduced accuracy in immunocompromised patients can affect their diagnostic performance. Furthermore, standardized antigens are lacking, and sensitivity can vary when using antigens from different species or non-autochthonous strains [5,6].

Taken together, these limitations underscore the need for rapid, specific, and less infrastructure- and personnel-dependent complementary diagnostic approaches. Molecular methods offer the potential to overcome several of these limitations by enabling the direct, objective detection of fungal DNA, thus supporting timely detection.

In this context, isothermal molecular amplification methods such as recombinase polymerase amplification (RPA) presents a promising molecular approach for such settings. This isothermal technique operates at a constant low temperature (typically 37–42°C) and delivers results in 20–30 minutes, requiring minimal equipment [12]. Its compatibility with direct visual detection and successful application across diverse pathogens make it particularly suitable for resource-limited contexts [13–20].

While loop-mediated amplification (LAMP) has been explored for *Paracoccidioides* [21,22] as an isothermal alternative, RPA-based detection has not been reported for this fungus. Here, we present the development and optimization of a frugal RPA assay for the detection of *Paracoccidioides* spp. DNA, targeting a 242 bp fragment of the ITS region. This integrates a simplified sample preparation method using crude fungal biomass from routine cultures, a miniaturized reaction volume that reduces reagent consumption, and SYBR Green I for direct UV-based visualization from reaction tubes.

2. Materials and methods

2.1. Fungal isolates and DNA extraction

Four clinical isolates of *Paracoccidioides* spp., two from acute/subacute forms (IMR-M-Pb 369 and IMR-M-Pb 473) and two from chronic forms (IMR-M-Pb 243 and IMR-M-Pb 611) were obtained from the culture collection of the Mycology Department at the Instituto de Medicina Regional, Universidad Nacional del Nordeste, Argentina. The strain IMR-M-Pb 369, sequenced and classified as S1 (GenBank accession number: JBICBQ000000000), served as positive control. Pb01 (*P. lutzii*), Pb339 (*P. brasiliensis* PS3), PbCNH (*P. brasiliensis* PS3), ATCC 60855 (*P. brasiliensis* PS3) were also included. For isolate metadata, see S1 Table.

Genomic DNA was extracted using our previously established protocol [11]. To minimize overall assay time and reagent use, a simplified extraction protocol for direct amplification from fungal biomass was adapted from Daddy Gaoh et al. [23] and Yang et al. [17]. Briefly, 0.3 g of yeast-phase biomass was resuspended in 500 µL of nuclease-free water in a 2 mL screw-cap tube and subjected to one freeze-boil cycle (20 min at -20 °C, then 10 min at 100 °C). After cooling and clarification, 1 µL of supernatant was used directly as RPA template. A detailed protocol is provided in S1 File.

2.2. Primer design and specificity evaluation

Following the TwistAmp Basic Kit (TwistDx, UK) guidelines, a pair of oligonucleotides for RPA was designed using NCBI Primer-BLAST [24], targeting a 242 bp genus-specific internal transcribed spacer (ITS) fragment from *Paracoccidioides*. Primer specificity was evaluated *in silico* against the NCBI nucleotide (nt) database, using the BLASTn tool [25]. Particular attention was paid to potential matches with *Homo sapiens* and relevant microorganisms, including *Leishmania* sp., *Coccidioides* sp., *Histoplasma* sp., *Aspergillus* sp., *Sporothrix* sp., *Mycobacterium tuberculosis*, *Emmonsia* sp., and *Fusarium* sp. Amplification was empirically tested using genomic DNA from different *Paracoccidioides* species. To assess potential cross-reactivity, DNA from phylogenetically related fungi (*Emmonsia* sp. and *Fusarium* sp.), as well as from common pathogens causing similar clinical presentations in PCM-endemic regions (*Leishmania* sp., *Coccidioides* sp., and *Histoplasma* sp.), was included.

2.3. Primer validation and RPA assay miniaturization

Primers were initially tested by conventional PCR using the T-Plus Free DNA Polymerase 500U Kit (Inbio Highway, Argentina). Reactions contained: 5 µL of TAS buffer (10X), 1 µL of $MgCl_2$ (25 mM), 1 µL of Taq DNA polymerase (5000 U/ml), 1 µL of dNTP mix (10 mM), 0.5 µL of each primer (10 µM), DNA template (approximately 100 ng), and water to a final volume of 25 µL. Thermocycling conditions were: 95 °C for 2 min; 35 cycles of 95 °C for 30 s, 60 °C for 30 s, 72 °C for 1 min; final extension at 72 °C for 5 min. After PCR validation, primers were tested in RPA reactions using the TwistAmp Basic Kit (TwistDx, UK), following the manufacturer's protocol: 29.5 µL of rehydration buffer, 2.4 µL of primers F and R (10 µM), DNA template and water to 13.2 µL, and 2.5 µL of MgOAc (280 mM). Reactions were incubated for 20 min at 37°C [15]. Subsequently, reaction volumes were scaled down from 50 µL to 8 µL to enhance cost-effectiveness. Amplification products were analyzed by 2% agarose gel electrophoresis and confirmed by Sanger sequencing (Macrogen, Korea). Base-calling reliability was assessed by the Phred quality score (Q) using Ridom TraceEdit [26], and alignments were performed with BioEdit [27] and Aliview v1.28 [28]. Genus-level identity was evaluated by BLAST analysis against the NCBI database.

2.4. Robustness assessment

RPA assay robustness was evaluated by testing performance under two conditions: direct amplification from crude fungal extract (Section 3.1) and volume miniaturization (Section 3.3). Additionally, to assess whether increased cell wall disruption improved DNA release and assay performance, the standard one freeze-boil cycle was compared against three consecutive freeze-boil cycles. For this comparison, 1 µL of lysate was added to 7 µL of RPA master mix, resulting in a final reaction volume of 8 µL.

2.5. Direct SYBR Green I-based visual detection and limit of detection (LoD) assessment

To further reduce consumables and equipment requirements, endpoint detection was performed directly from RPA reaction tubes. For this, SYBR Green I (Invitrogen, USA) was used at a final concentration of 50X [18], with primers adjusted to 0.12 µM each, following SYBR Green I-optimized RPA work by Zheng et al. [12]. To determine the LoD, 10-fold serial dilutions of *Paracoccidioides* genomic DNA (10–1×10^{-6} ng/µL), non-template controls (NTC), and a heterologous negative control containing *Leishmania* DNA (1 ng/µL) were prepared. From each, 1 µL was used as template in the final 8 µL RPA reaction. All reactions were performed in triplicate, following the empirical approach described by Jarvi et al. [29]. Fluorescence was inspected visually under natural and UV illumination [18] and assessed as Relative Fluorescence Units (RFU) using a Qubit fluorometer (Thermo Fisher Scientific, Waltham, MA, USA) according to Oshiki et al. [30]. The limit of blank (LoB) was calculated from NTC raw RFU values as: $LoB = mean(NTC) + 3 \times SD(NTC)$, following Jarvi et al. [29]. Correlation analysis was performed on RFU versus $\log_{10}$-transformed total DNA input per reaction, across a five-point

range (10–1 × 10^{-3} ng). Analyses were completed in Python 3.11 [31] and cross-checked in InfoStat v2020 [32]. Graphical designs were adapted from Daddy Gaoh et al. [23] and Oshiki et al. [30]. The empirical LoD was defined as the lowest total DNA input per reaction resulting in detectable amplification in all technical replicates (3/3), in accordance with Jarvi et al. [29]. Presence of the 242 bp amplicon was confirmed on 2% agarose gel electrophoresis stained with GelRed (Genbiotech, Argentina).

3. Results

3.1. Primer design and *in silico* specificity

Genus-specific primers were successfully designed to target the ITS region of *Paracoccidioides*. *In silico* analysis confirmed their ability to generate a 242 bp amplicon specific to *Paracoccidioides* entries in NCBI databases. Although minor homology was observed with *Emmonsia* and *Fusarium* species, discriminatory sequence positions were selected during primer design to ensure high specificity for the target genus. Nonetheless, these heterologous fungi were included as critical negative controls to experimentally validate assay specificity. The primer sequences are as follows:

Forward: 5′-CGTGCCCGCCGGGGACACCGTTGAACTTCTGGTTC-3′ and

Reverse: 5′-CGCTTGAGGGTTGAAATGACGCTCGGACAGGCATG-3′

3.2. RPA assay specificity and optimization

Our RPA assay demonstrated high specificity when tested against a panel of phylogenetically related and clinically relevant pathogens, with no cross-reactivity detected against DNA from *Leishmania* sp., *Coccidioides* sp., *Histoplasma* sp., *Fusarium* sp., or *Emmonsia* sp. (Fig 1A). Successful amplification was achieved for all tested *Paracoccidioides* spp.



Fig 1. RPA assay optimization and specificity evaluation using DNA from cultures. (A) Specificity testing in the 50 µL reaction format. Lane 1: non-template control (NTC); lane 2: 1 ng of *Paracoccidioides brasiliensis* S1 (IMR-M-Pb 369, Argentina); lane 3: 0.1 ng of *P. brasiliensis* S1 (IMR-M-Pb 369); lane 4: *Leishmania* sp.; lane 5: *Coccidioides* sp.; lane 6: *Emmonsia* sp.; lane 7: *Histoplasma* sp.; lane 8: *Fusarium* sp.; lane 9: 100 bp DNA ladder (Inbio Highway, Argentina). Background from viscous RPA mixture is visible in lane 1. **(B)** Assay performance of the miniaturized 8 µL reactions with approximately 100ng of DNA input. Lane 1: NTC; lane 2: *P. lutzii* (Pb01, Brazil); lanes 3-4: *P. brasiliensis* clinical isolates (IMR-Pb-473 and IMR-Pb-611, Northern Argentina); lane 5: *P. brasiliensis* PS3 (Pb339, Brazil); lane 6: *P. brasiliensis* PS3 (Pblish, Colombia); lane 7: *P. brasiliensis PS3* (ATCC 60855, Colombia); lane 8: *P. brasiliensis* IMR-Pb-243 (Peru); lane 9: 100 bp DNA ladder (Inbio Highway, Argentina). *This figure was created specifically for this study by the corresponding author and is made available under a Creative Commons Attribution 4.0 International (CC BY 4.0) license*.

https://doi.org/10.1371/journal.pntd.0014101.g001

strains, including *P. brasiliensis* S1 (IMR-M-Pb 369), P. *brasiliensis* PS3, and *P. lutzii* (Fig 1B). Furthermore, scaling down the reaction volume from 50 µL to 8 µL reduced reagent costs per sample while eliminating non-specific background observed in larger volumes (Fig 1A, 1B).

3.3. Limit of detection (LoD)

Endpoint visualization by direct addition of SYBR Green I to reaction tubes enabled clear detection of amplification under UV illumination down to 1 pg of DNA per 8 µL reaction (Fig 2A). Agarose gel electrophoresis reproducibly showed the expected 242 bp amplicon down to 10 pg per reaction, with light bands observable at 1 pg (Fig 2B). Qubit fluorometric



Fig 2. Analytical performance of the endpoint miniaturized RPA assay for *Paracoccidioides* spp. (A) Direct fluorescence detection under UV light after SYBR Green I addition into the 8 µL reaction tubes. Tubes contain: 1, non-template control (NTC); 2, negative control (1 ng of *Leishmania* sp. DNA); 3 to 10, ten-fold decreasing series of *Paracoccidioides* genomic DNA inputs: 10 ng, 1 ng, 100 pg, 10 pg, 1 pg, 100 fg, 10 fg, and 1 fg per reaction, respectively. Fluorescence was clearly distinguishable down to 1 pg. **(B)** Agarose gel electrophoresis (2%) of amplification products from reactions with decreasing DNA inputs. Lanes 1 and 12: 50 bp DNA ladder (Inbio Highway, Argentina); Lane 2: NTC; Lane 3: negative control (1 ng of *Leishmania* sp. DNA); Lanes 4 to 11: 10 ng to 1×10^{-6} ng (1 fg) of *Paracoccidioides* DNA. The 242 bp target band is visible from lane 4 (10 ng) down to lane 8 (1 pg). **(C)** Fluorometric assessment (Qubit) of technical triplicates; RFU values decreased progressively with lower DNA inputs, confirming successful amplification across the series. The dashed horizontal line indicates the limit of blank (LoB = 20,148 RFU), calculated as mean(NTC) + 3 × SD(NTC). **(D)** Fluorometric signal trend across DNA inputs. The observed decrease in RFU values with lower DNA input, corroborated by a strong positive correlation ($r = 0.96$; $p = 0.0077$), demonstrates the assay's consistent performance across the tested range. The empirical LoD (3/3 positives) corresponds to 1 pg per 8 µL RPA reaction. Negative controls remained below the LoB. *This figure was created specifically for this study by the corresponding author and is made available under a Creative Commons Attribution 4.0 International (CC BY 4.0) license.*

https://doi.org/10.1371/journal.pntd.0014101.g002

assessment confirmed successful amplification, with RFU values progressively decreasing with lower DNA input (Fig 2C). This trend was corroborated by a strong positive correlation ($r = 0.96$; $p = 0.0077$) between RFU values and the logarithm of the DNA input (Fig 2D), which demonstrates the assay's consistent performance across the tested range. The limit of blank (LoB) was calculated as 20,148 RFU. The empirical LoD was established at 1 pg per reaction, the lowest DNA input yielding positive results in all replicates. Heterologous negative controls (*Leishmania* sp.) remained below the LoB, confirming specificity. Importantly, due to its consistent fluorescence and superior sensitivity, the UV-based detection method using SYBR Green I at a 50X concentration was selected for all subsequent experiments. In contrast, ambient-light visualization of results was inconsistent and insufficient for reliable endpoint determination, as it required significantly higher concentrations of amplicon and dye, thereby increasing assay cost without guaranteeing a clear result.

3.4. Assay robustness: performance with crude extracts in miniaturized reactions

The RPA assay coupled with the rapid extraction protocol successfully detected the genus *Paracoccidioides* across cultures from different lineages, including *P. lutzii*, *P. brasiliensis* PS3, and the *P. brasiliensis* S1 positive control IMR-M-Pb 369 (Fig 3A), demonstrating broad applicability to routine isolates. Moreover, this approach reduced processing time compared with the conventional DNA extraction method and maintained robust performance in a miniaturized 8 µL reaction format without non-specific background. Notably, occasional increased signal intensity was observed following three consecutive freeze-boil cycles compared to a single cycle, suggesting that additional cell-wall disruption can moderately improve DNA release in certain cases (Fig 3B).

3.5. Sequence identity confirmation of RPA amplicons

The identity of all RPA amplicons was confirmed by Sanger sequencing, including those from both genomic DNA extracted using our prior protocol, and from crude fungal lysates processed with the freeze-boil method. Base quality assessed by Ridom TraceEdit was consistently high, with the majority of bases achieving quality scores above Q30. The few bases with quality lower than Q30 were manually checked and resolved by electropherogram inspection. All sequences were confirmed as belonging to the *Paracoccidioides* genus by subsequent BLASTn analysis and were deposited in GenBank



Fig 3. RPA assay directly from culture extracts. (A) SYBR Green I fluorescence under UV light observed directly in reaction tubes. Tube: 1, non-template control (NTC); tubes 2-3: *Paracoccidioides brasiliensis S1* (1 and 3 freeze-boil cycles); tubes 4-5: *P. brasiliensis* PS3 (1 and 3 cycles); tubes 6-7: *P. lutzii* (3 and 1 cycles). **(B)** Agarose gel electrophoresis of corresponding amplification products. Lane 1: 100 bp DNA ladder (Inbio Highway, Argentina); lane 2: NTC; lanes 3-4: *P. brasiliensis* S1 (1 and 3 cycles); lanes 5-6: *P. brasiliensis* PS3 (1 and 3 cycles); lanes 7-8: *P. lutzii* (3 and 1 cycles). The expected 242 bp amplicon is indicated. Electrophoresis conditions: 2% agarose gel stained with GelRed, 100 V for 55 min. *This figure was created specifically for this study by the corresponding author and is made available under a Creative Commons Attribution 4.0 International (CC BY 4.0) license.*

https://doi.org/10.1371/journal.pntd.0014101.g003

(accession numbers: PX684487 - PX684497). Fungal isolate metadata are provided in S1 Table. Multiple sequence alignment of the ITS fragments confirmed a high degree of sequence conservation across the phylogenetic lineages tested, as demonstrated in S2 File.

4. Discussion

The diagnosis of PCM remains critically hindered by reliance on conventional methods with well-documented limitations [5]. In this context, molecular methods have increasingly been proposed as valuable complementary tools to classical mycological and serological approaches. Studies have demonstrated that PCR- and RT-PCR–based assays can improve diagnostic sensitivity and support case confirmation, particularly in complex clinical scenarios and in non-endemic areas where clinical suspicion is low [33–35]. However, despite their analytical performance, most reported molecular assays for PCM rely on thermocycler-dependent platforms, quantitative instrumentation, or multi-step workflows, limiting their routine implementation in low-complexity laboratories in endemic regions. This gap underscores the need for alternative molecular approaches that combine specificity with operational simplicity and affordability. With this objective, we have developed an RPA assay that prioritizes minimal equipment usage, cost-effectiveness, and operational simplicity, while maintaining robust analytical performance.

RPA has been successfully used to detect multiple infectious agents, including bacterial and parasitic pathogens, in both clinical and field settings [13–20]. In these contexts, RPA-based assays have been employed as rapid confirmatory tools or screening methods, particularly when conventional molecular platforms are not readily available. These prior applications establish RPA as a mature, and adaptable molecular amplification strategy, providing a relevant framework for its extension to neglected systemic mycoses such as PCM.

Isothermal amplification methods represent a practical alternative to conventional PCR, as they eliminate the need for a thermocycler, reducing initial costs and enabling portable use. LAMP has been successfully explored for the detection of *Paracoccidioides brasiliensis* [21,22], and offers advantages such as a rapid turnaround time, simple equipment requirements and user-friendly readouts. However, RPA provides a distinct and complementary operational profile. LAMP requires more primers, operates at higher temperature (63 °C), and involves longer overall assay time. Our RPA-based approach achieves robust genus-specific amplification at a lower, constant temperature (approximately 37 °C) and delivers amplification in shorter timeframes, simplifying reagent complexity and implementation while reducing equipment needs and consumable expenses. This is particularly advantageous in resource-constrained endemic settings where precise temperature control and thorough sample preparation can be challenging. Furthermore, RPA requires only two primers, which simplifies assay design and optimization compared to LAMP, which typically relies on four to six primers and more complex interactions. The choice between LAMP and RPA will depend on local infrastructure, operational constraints, and economics.

The cornerstone of our assay's reliability lies in its primer design, which is particularly critical for the *Paracoccidioides* genus given the significant genomic heterogeneity among its species [1]. This complexity is further underscored by recent genomic analysis [36], which supports the highly dynamic nature of the nuclear genome, shaped by both large-scale chromosomal rearrangements, such as fusions and fissions, and the differential activity of transposable elements. By targeting conserved regions within the ITS locus, we achieved comprehensive detection across major phylogenetic lineages while maintaining high specificity against common cross-reactive pathogens. This strategic target selection addresses a notable limitation in the molecular identification of *Paracoccidioides*, where conventional targets like gp43 exhibit excessive variability that can compromise reliable genus-level detection [4]. In this context, the consistent amplification across multiple species and geographic origins validates our bioinformatic design and supports the assay's applicability throughout endemic regions. Critically, Sanger sequencing confirmed the identity of all RPA amplicons as belonging to the *Paracoccidioides* genus and the conserved nature of the targeted region, providing essential verification. This is crucial given RPA's tolerance to primer-template mismatches, which can promote non-specific amplification [37]. The high-quality

chromatograms (Q30+) confirm that our optimized conditions mitigated these risks across amplification from both purified DNA and crude lysates. Multiple-sequence alignment further confirmed the expected conservation of the ITS region. However, validation gaps remain: the absence of PS2 and PS4 species in our sample set may introduce uncertainty regarding universal detection. Given the high conservation of the targeted ITS region, the detection of these lineages is expected, but clinical work should prioritize the evaluation of these lineages, present in other Latin American regions but not yet reported in Argentina [1].

Furthermore, we believe our methodological optimizations exemplify a frugal science approach, strategically balancing cost and performance to develop a practical tool for low-resource endemic settings. The substantial reduction to 8 µL reaction volumes provided dual benefits: minimizing non-specific amplification artifacts while drastically cutting per-test costs. This is in accordance with Lai & Lau [20], who demonstrated that volumes as low as 6.25 µL maintain amplification efficiency. The combination of miniaturization and UV-based SYBR Green I detection establishes an economically sustainable system. The one-time investment in a simple UV lamp provides greater cost-effectiveness compared to recurring expenses associated with specialized single-use detection formats. Notably, Jiang et al. [18] report that very low SYBR Green I concentrations, such as 0.16X, can be used for UV detection, which would further reduce costs per reaction. However, due to resource constraints that limited our capacity for extensive optimization, we prioritized the 50X concentration identified by these authors as the most robust condition. This finding nevertheless underscores the potential for even greater cost reduction, making this approach cost-effective compared to other molecular detection alternatives.

A practical advantage for resource-limited settings is the assay's compatibility with simplified sample processing. We demonstrated that reliable detection is achievable directly from crude freeze-boil lysates, bypassing costly extraction kits and reducing processing time associated with conventional or commercial DNA extraction methods. Improvements in signal intensity observed after additional freeze-boil cycles suggest an accessible optimization strategy for difficult-to-lyse isolates. This approach leverages the routine fungal cultures already established in endemic areas, creating a powerful molecular confirmation step without requiring substantial new infrastructure.

With a limit of detection of 1 pg of DNA per 8 µL reaction, the assay is less sensitive than ITS1-targeted qPCR [33]. Nevertheless, it remains a practical alternative as it enables rapid and robust amplification from minimal crude culture extracts. This aspect is particularly relevant given the slow growth of *Paracoccidioides* cultures [5]. By prioritizing workflow simplicity and cost reduction, the design is well-suited for frontline use. The strong correlation between template input and fluorescence signal ($r = 0.96$, $p = 0.0077$) confirms the assay's reliable performance across the tested range.

As with all nucleic acid amplification techniques, the proposed RPA-based assay has technical and operational limitations that must be considered. One potential cause of false-positive results is carryover contamination, especially in workflows involving the handling of open tubes. However, the short assay time of this technique and the endpoint visualization directly in closed reaction tubes, reduce post-amplification handling and can mitigate this risk compared to conventional PCR. Conversely, false-negative results could occur when using clinical samples with a very low fungal load or inefficient DNA release, or when amplification inhibitors are present in complex biological matrices.

Other limitations include potential variability related to reagent stability, batch-to-batch consistency, and workflow standardization. These limitations can affect reproducibility when the assay is implemented in different laboratories or field settings. It is important to note that, since this study focuses on analytical development and specificity using culture-derived DNA, diagnostic sensitivity, specificity, and reproducibility in clinical samples have not yet been formally established. These parameters will require systematic evaluation during subsequent clinical validation with well-characterized patient samples.

This assay was primarily designed for future use in low-complexity laboratories where access to molecular diagnostics is limited. In this context, the assay was conceived as an analytical development and feasibility assessment, aimed at establishing technical robustness, specificity, and operational simplicity. While clinical metadata of the isolates is provided, this study does not evaluate diagnostic sensitivity across clinical forms or tissue types, because amplification was

performed on culture-derived DNA. Therefore, the next essential phase of this research is clinical validation using samples from patients with acute and chronic PCM. This validation should include a comparison with established diagnostic methods and an estimation of diagnostic performance parameters, such as sensitivity and specificity. The future integration of a frugal DNA extraction strategy for clinical samples with our RPA assay would further enable a fully accessible and affordable diagnostic pipeline for PCM in resource-limited endemic settings.

Finally, we believe that this work goes beyond technical optimization and serves as a case study in developing context-appropriate methods. By systematically addressing the economic, infrastructural, and operational constraints of PCM-endemic regions, we developed a practical tool tailored to the environments where it is needed most. We hope that our frugal RPA assay represents a significant step toward equitable molecular diagnostics for this neglected disease, demonstrating that strategic, context-aware innovation can help bridge the gap between novel techniques and the underserved populations who bear the greatest burden.

5. Conclusion

This study presents an RPA assay specifically developed for the genus-level detection of *Paracoccidioides* spp., tested across major phylogenetic lineages, with no cross-reactivity to related pathogens. By targeting a conserved ITS region, the assay achieves a sensitive, specific, and robust workflow suitable for laboratories in resource-limited endemic settings.

Through a frugal and context-appropriate scientific approach, we designed a cost-effective solution while preserving analytical performance. This was achieved by combining reaction miniaturization to 8 µL with UV-based endpoint detection and a simple freeze-boil lysis strategy that substantially reduces per-test costs. A LoD of 1 pg of total DNA input per 8 µL reaction was consistently demonstrated through three independent readouts: direct tube visualization, gel electrophoresis, and fluorometry.

While validated on culture-derived material, the assay's core function, the specific detection of *Paracoccidioides* DNA, positions it as a versatile tool ready for integration with future frugal DNA extraction methods from clinical samples. Overall, this assay represents a meaningful step toward expanding molecular diagnostic capacity for PCM in underserved regions.

Supporting information

S1 File. Rapid DNA extraction from *Paracoccidioides* spp. yeast cultures using a freeze–boil method. Detailed protocol describing a simplified thermal shock–based DNA extraction procedure used prior to RPA assays.
(DOCX)

S2 File. Multiple sequence alignment of the RPA-amplified ITS target region from *Paracoccidioides* isolates after trimming primer sequences. The conserved region and single nucleotide polymorphisms (SNPs) are shown.
(DOCX)

S1 Table. Metadata of *Paracoccidioides* spp. isolates used in this study and clinical characteristics of the corresponding patients. The table includes isolate origin, species or lineage assignment, DNA extraction method, GenBank accession numbers, and relevant clinical information.
(DOCX)

Acknowledgments

We express our sincere gratitude to all colleagues whose collaboration made this work possible. We thank Juan Solá, Jorge Gnus, and Matías Paredes for coordinating the long-distance supply of essential reagents. We are deeply grateful to the co-authors from institutions across Argentina, who generously shared reagents and expertise despite significant

budgetary and logistical constraints. Their commitment to collaborative research was fundamental to the completion of this study. We also thank the Department of Mycology, INEI-ANLIS "Dr. Carlos G. Malbrán", (Buenos Aires, Argentina) for providing DNA from multiple microorganisms for cross-reactivity testing. This work illustrates the importance of interdisciplinary cooperation and collective effort in advancing diagnostic tools for neglected diseases.

Author contributions

Formal analysis: Melina Noelia Lorenzini Campos, Raúl Maximiliano Acevedo, Gabriela Alejandra Massa, Mario Alberto Piz.

Funding acquisition: Gustavo Giusiano.

Investigation: Melina Noelia Lorenzini Campos.

Methodology: Melina Noelia Lorenzini Campos, Raúl Maximiliano Acevedo, Gabriela Alejandra Massa.

Project administration: Gustavo Giusiano.

Resources: Raúl Maximiliano Acevedo, Gabriela Alejandra Massa, Laura Elena Valinotto, Luis Hernando Corredor Sanguña, Raúl Horacio Lucero, Florencia Rojas, Laura Belén Formichelli, Liliana Silvina Lösch, Javier Esteban Mussin, Gustavo Giusiano.

Software: Mario Alberto Piz.

Supervision: Gabriela Alejandra Massa, Gustavo Giusiano.

Validation: Melina Noelia Lorenzini Campos.

Visualization: Melina Noelia Lorenzini Campos.

Writing – original draft: Melina Noelia Lorenzini Campos.

Writing – review & editing: Melina Noelia Lorenzini Campos, Raúl Maximiliano Acevedo, Gabriela Alejandra Massa, Laura Elena Valinotto, Gustavo Giusiano.

References

1. Teixeira M de M, Cattana ME, Matute DR, Muñoz JF, Arechavala A, Isbell K, et al. Genomic diversity of the human pathogen Paracoccidioides across the South American continent. Fungal Genet Biol. 2020;140:103395. https://doi.org/10.1016/j.fgb.2020.103395 PMID: 32325168
2. Griffiths J, Lopes Colombo A, Denning DW. The case for paracoccidioidomycosis to be accepted as a neglected tropical (fungal) disease. PLoS Negl Trop Dis. 2019;13(5):e0007195. https://doi.org/10.1371/journal.pntd.0007195 PMID: 31095569
3. World Health Organization. WHO fungal priority pathogens list to guide research, development and public health action. Geneva: World Health Organization; 2022.
4. Gonçalves Pinheiro B, Hahn RC, Camargo ZP, Rodrigues AM. Molecular tools for detection and identification of *Paracoccidioides* species: current status and future perspectives. J Fungi (Basel). 2020;6(4):293.
5. Giusiano G, Tracogna F, Santiso G, Rojas F, Messina F, Sosa V, et al. Clinical and Demographic Features of Paracoccidioidomycosis in Argentina: A Multicenter Study Analysis of 466 Cases. J Fungi (Basel). 2023;9(4):482. https://doi.org/10.3390/jof9040482 PMID: 37108936
6. Peçanha PM, Peçanha-Pietrobom PM, Grão-Velloso TR, Rosa Júnior M, Falqueto A, Gonçalves SS. Paracoccidioidomycosis: What We Know and What Is New in Epidemiology, Diagnosis, and Treatment. J Fungi (Basel). 2022;8(10):1098.
7. Romaneli MT das N, Tardelli NR, Tresoldi AT, Morcillo AM, Pereira RM. Acute-subacute paracoccidioidomycosis: A paediatric cohort of 141 patients, exploring clinical characteristics, laboratorial analysis and developing a non-survival predictor. Mycoses. 2019;62(11):999–1005. https://doi.org/10.1111/myc.12984 PMID: 31408548
8. Pereira RM, Bucaretchi F, Barison E de M, Hessel G, Tresoldi AT. Paracoccidioidomycosis in children: clinical presentation, follow-up and outcome. Rev Inst Med Trop Sao Paulo. 2004;46(3):127–31. https://doi.org/10.1590/s0036-46652004000300002 PMID: 15286812
9. Puccia R, Vallejo MC, Matsuo AL, Longo LVG. The *Paracoccidioides* cell wall: past and present layers toward understanding interaction with the host. Front Microbiol. 2011;2:257. https://doi.org/10.3389/fmicb.2011.00257 PMID: 22194733
10. Baer SL, Pappas PG. Hematogenously disseminated fungal infections. In: Clinical Mycology. 2nd edition. Elsevier; 2009. p. 609–22.

11. Lorenzini Campos MN, Amadio AF, Irazoqui JM, Acevedo RM, Rojas FD, Corredor Sanguña LH, et al. Applying nanopore sequencing technology in Paracoccidioides sp.: a high-quality DNA isolation method for next-generation genomic studies. Microb Genom. 2024;10(10):001302. https://doi.org/10.1099/mgen.0.001302 PMID: 39432409
12. Zheng Y, Hu P, Ren H, Wang H, Cao Q, Zhao Q, et al. RPA-SYBR Green I based instrument-free visual detection for pathogenic Yersinia enterocolitica in meat. Anal Biochem. 2021;621:114157. https://doi.org/10.1016/j.ab.2021.114157 PMID: 33705723
13. Azinheiro S, Roumani F, Rodríguez-Lorenzo L, Carvalho J, Prado M, Garrido-Maestu A. Combination of Recombinase Polymerase Amplification with SYBR Green I for naked-eye, same-day detection of Escherichia coli O157:H7 in ground meat. Food Control. 2022;132:108494. https://doi.org/10.1016/j.foodcont.2021.108494
14. Geng Y, Tan K, Liu L, Sun XX, Zhao B, Wang J. Development and evaluation of a rapid and sensitive RPA assay for specific detection of Vibrio parahaemolyticus in seafood. BMC Microbiol. 2019;19(1):186. https://doi.org/10.1186/s12866-019-1562-z PMID: 31409301
15. Chen X, Zhao L, Wang J, Wang H, Qiu Y, Dong Z, et al. Rapid visual detection of anisakid nematodes using recombinase polymerase amplification and SYBR Green I. Front Microbiol. 2022;13:1026129. https://doi.org/10.3389/fmicb.2022.1026129 PMID: 36532447
16. Hu S, Yan C, Yu H, Zhang Y, Zhang C-Q. Establishment of the Recombinase Polymerase Amplification-Lateral Flow Dipstick Detection Technique for Fusarium oxysporum. Plant Dis. 2023;107(9):2665–72. https://doi.org/10.1094/PDIS-12-22-2841-RE PMID: 36774580
17. Yang X, Zhang X, Wang Y, Shen H, Jiang G, Dong J, et al. A Real-Time Recombinase Polymerase Amplification Method for Rapid Detection of Vibrio vulnificus in Seafood. Front Microbiol. 2020;11:586981. https://doi.org/10.3389/fmicb.2020.586981 PMID: 33240242
18. Jiang L, Wang P, Zhang G, Niu X, Liu Q, Liang R, et al. Rapid visual detection of bovine viral diarrhea virus (BVDV) using recombinase polymerase amplification with SYBR green I. BMC Vet Res. 2025;21(1):232. https://doi.org/10.1186/s12917-025-04640-z PMID: 40169998
19. Singpanomchai N, Akeda Y, Tomono K, Tamaru A, Santanirand P, Ratthawongjirakul P. Naked eye detection of the Mycobacterium tuberculosis complex by recombinase polymerase amplification-SYBR green I assays. J Clin Lab Anal. 2019;33(2):e22655. https://doi.org/10.1002/jcla.22655 PMID: 30129085
20. Lai MY, Lau YL. Detection of Plasmodium knowlesi using recombinase polymerase amplification (RPA) combined with SYBR Green I. Acta Trop. 2020;208:105511. https://doi.org/10.1016/j.actatropica.2020.105511 PMID: 32422380
21. Endo S, Komori T, Ricci G, Sano A, Yokoyama K, Ohori A, et al. Detection of gp43 of Paracoccidioides brasiliensis by the loop-mediated isothermal amplification (LAMP) method. FEMS Microbiol Lett. 2004;234(1):93–7. https://doi.org/10.1016/j.femsle.2004.03.015 PMID: 15109725
22. Kanegae H, Suguiura Im De S, Minakawa T, Augusuto OM, Itano En, Wada S, et al. Confirmation of a Suspected Case of Paracoccidioidomycosis Ceti by a Combination of Polymerase Chain Reaction and Loop-mediated Isothermal Amplification (PCR-LAMP) Analysis. Jpn J Zoo Wildl Med. 2021;26(4):103–11. https://doi.org/10.5686/jjzwm.26.103
23. Daddy Gaoh S, Kweon O, Ahn Y. Propidium monoazide (PMAxx)-recombinase polymerase amplification exo (RPA exo) assay for rapid detection of Burkholderia cepacia complex in chlorhexidine gluconate (CHX) and benzalkonium chloride (BZK) solutions. Microorganisms. 2023;11(6):1401.
24. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics. 2012;13:134. https://doi.org/10.1186/1471-2105-13-134 PMID: 22708584
25. Johnson M, Zaretskaya I, Raytselis Y, Merezhuk Y, McGinnis S, Madden TL. NCBI BLAST: a better web interface. Nucleic Acids Res. 2008;36(Web Server issue):W5–9. https://doi.org/10.1093/nar/gkn201 PMID: 18440982
26. Rothgänger J, Weniger M, Weniger T, Mellmann A, Harmsen D. Ridom TraceEdit: a DNA trace editor and viewer. Bioinformatics. 2006;22(4):493–4. https://doi.org/10.1093/bioinformatics/btk002 PMID: 16357036
27. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser. 1999;41:95–8.
28. Larsson A. AliView: a fast and lightweight alignment viewer and editor for large datasets. Bioinformatics. 2014;30(22):3276–8. https://doi.org/10.1093/bioinformatics/btu531 PMID: 25095880
29. Jarvi SI, Atkinson ES, Kaluna LM, Snook KA, Steel A. Development of a recombinase polymerase amplification (RPA-EXO) and lateral flow assay (RPA-LFA) based on the ITS1 gene for the detection of Angiostrongylus cantonensis in gastropod intermediate hosts. Parasitol Res. 2020;119(11):3589–98.
30. Oshiki M, Fukushima T, Kawano S, Nakagawa J. Endpoint Recombinase Polymerase Amplification (RPA) Assay for Enumeration of Thiocyanate-degrading Bacteria. Microbes Environ. 2022;37(1):ME21073. https://doi.org/10.1264/jsme2.ME21073 PMID: 35264493
31. Virtanen P, Gommers R, Oliphant TE, et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat Methods. 2020;17(3):261–72.
32. Di Rienzo JA, Casanoves F, Balzarini MG, González L, Tablada M, Robledo CW. InfoStat version 2020. Argentina: Centro de Transferencia InfoStat, FCA, Universidad Nacional de Córdoba; 2020.
33. Buitrago MJ, Merino P, Puente S, Gomez-Lopez A, Arribi A, Zancopé-Oliveira RM, et al. Utility of real-time PCR for the detection of Paracoccidioides brasiliensis DNA in the diagnosis of imported paracoccidioidomycosis. Med Mycol. 2009;47(8):879–82. https://doi.org/10.3109/13693780802713208 PMID: 19184775
34. Marques de Macedo P, Sturny-Leclère A, Hamane S, Pautet T, Rodrigues AM, Freitas DFS, et al. A new quantitative reverse transcription PCR assay to improve the routine diagnosis of paracoccidioidomycosis. Med Mycol. 2024;63(1):myae125. https://doi.org/10.1093/mmy/myae125 PMID: 39779281

35. Fernández NB, Toranzo A, Farias L, Canteros CE. Mycological diagnosis of paracoccidioidomycosis in a hospital from a nonendemic area: classical and molecular methods. Biomedica. 2023;43(Sp. 1):132–43. https://doi.org/10.7705/biomedica.6888 PMID: 37721907

36. Grinevich D, Kompathoum O, Li J, Turissini DA, Kelly P, Sutherland M, et al. Telomeric assemblies of Paracoccidioides genomes. bioRxiv. 2025;2025.10.30.685552. https://doi.org/10.1101/2025.10.30.685552 PMID: 41278805

37. Li J, Macdonald J, von Stetten F. Review: a comprehensive summary of a decade development of the recombinase polymerase amplification. Analyst. 2018;144(1):31–67. https://doi.org/10.1039/c8an01621f PMID: 30426974